IBS C News and Research

RSS

Treatment for IBS proves difficult, survey reveals

A new national survey by Health Union of more than 1,000 individuals with Irritable Bowel Syndrome (IBS) reveals that the condition is difficult to diagnose and often even more difficult to treat.

29 Jun 2016

Researchers play crucial role in crafting diagnostic criteria for functional GI disorders

With no laboratory test available to diagnose functional gastrointestinal disorders, proper diagnostic criteria are critical for clinicians to make an accurate determination of what ails their patients.

22 Jun 2016

Tarantula venom could help provide relief for patients suffering from Irritable Bowel Syndrome

Researchers from The University of Adelaide in South Australia found that a specific peptide in the spider venom could be used to understand how people sense pain.

7 Jun 2016

Diet-based therapy may improve quality of life in IBS patients

A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.

25 May 2016

Set of 16 different substances in the breath can help identify IBS patients

There is currently no specific diagnostic test for irritable bowel syndrome (IBS), but now researchers have identified a combination of 16 different substances in the breath that, when measured together, can accurately distinguish IBS patients from people without the condition.

11 May 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Research shows probiotic B. longum KACC 91563 has ability to reduce effects of food allergies

Lactobacillus might sound familiar when the topic of probiotics comes up, but they are only one of many types of bacteria that have proven health benefits.

16 Mar 2016

Breast cancer can be more aggressive in obese people

An international team of researchers, with the participation of the University of Granada, has revealed new data on why breast cancer has a higher incidence and is more aggressive in obese people. The reason is that peritumoral fat (the fat around the tumor) facilitates the expansion and invasion of cancer stem cells (CSCs), which are responsible of the onset and growth of the tumor.

11 Mar 2016

Novel mitochondria-specific ceria nanoparticles can effectively suppress neuronal cell death

The brain is an enormous network of communication, containing over 100 billion nerve cells, or neurons, with branches that connect at more than 100 trillion points. They are constantly sending signals through a vast neuron forest that forms memories, thoughts and feelings; these patterns of activity form the essence of each person.

27 Feb 2016

Study: Migraine, tension-type headaches may share genetic links with IBS

Migraine and tension-type headaches may share genetic links with irritable bowel syndrome (IBS), according to a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

24 Feb 2016

10 million of us lack sunshine vitamin

Health pioneers BetterYou have welcomed the views of Nutritionist Marilyn Glenville, that ‘oil based supplements can help you get your recommended dose of vitamin D’.

From BetterYou Ltd 27 Jan 2016

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

First trials of smart gas sensing pills offer new clues for development of gut disorder treatments

Researchers have conducted the first ever trials of smart pills that can measure intestinal gases inside the body, with surprising results revealing some unexpected ways that fibre affects the gut.

13 Jan 2016

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.

5 Jan 2016

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

For some time doctors have known that psychological therapies can reduce the symptoms of irritable bowel syndrome in the short term.

29 Dec 2015

Study reveals molecular function of protein essential for replication of H5N1 flu virus

An international collaboration of scientists from the CEA, CNRS, University Joseph Fourier, the EMBL and the ILL has revealed the molecular function of a protein essential for replication of H5N1 influenza virus.

10 Dec 2015

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

1 Dec 2015

Loyola gastroenterologist provides tips to IBS patients for healthy living

More than 20 percent of the US population lives with irritable bowel syndrome (IBS) and for many Americans it is an ongoing challenge. But when it comes to treatment, old advice from Mom was right. Often, the key is to eat right and go outside and play.

16 Oct 2015

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Laboratories, LLC ("Commonwealth") announced today that it has formed an agreement with Quest Diagnostics ("Quest") that will expand the availability of IBSchek™, a new laboratory developed blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS).

From Quest Diagnostics 15 Oct 2015

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Sanofi notified Ardelyx of its termination of the option and license agreement for Ardelyx's portfolio of NaP2b inhibitors effective September 30, 2015.

2 Sep 2015